Skip to content
BiologicalX

Comparison

Testosterone vs Thymosin Alpha-1

Side-by-side of Testosterone and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Testosterone

  • Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
  • Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
  • TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
  • Schedule III controlled substance in US; WADA banned in sport
  • Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
  • Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect

Thymosin Alpha-1

  • 28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
  • Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
  • Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
  • Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
  • Standard label dose: 1.6 mg subcutaneously twice weekly
  • Cleanest safety profile in the peptide class with hundreds of regulated trials behind it

Side-by-side

Attribute Testosterone Thymosin Alpha-1
Category hormone peptide
Also known as TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim Talpha1, Ta1, Zadaxin, Thymalfasin
Half-life (hr) 192 2
Typical dose (mg) 150 1.6
Dosing frequency weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet) 2x weekly
Routes intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral subcutaneous, intramuscular
Onset (hr) 24 24
Peak (hr) 72 168
Molecular weight 288.42 3108.32
Molecular formula C19H28O2 C129H215N33O55
Mechanism Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects. Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells.
Legal status Schedule III controlled substance (US); WADA banned Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List
WADA status banned unknown
DEA / Rx Schedule III Rx only via international approval or US compounding (no controlled-substance schedule)
Pregnancy Category X; contraindicated in pregnancy (virilizing effect on female fetus) Not recommended; insufficient data
CAS 58-22-0 62304-98-7
PubChem CID 6013 16130571
Wikidata Q150726 Q913854

Safety profile

Testosterone

Common side effects

  • erythrocytosis
  • acne
  • oily skin
  • fluid retention
  • increased body hair
  • fertility suppression
  • injection-site reactions

Contraindications

  • active prostate cancer
  • active breast cancer
  • untreated severe sleep apnea
  • untreated severe BPH
  • uncontrolled heart failure
  • polycythemia at baseline

Interactions

  • warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
  • insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
  • 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
  • aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)

Thymosin Alpha-1

Common side effects

  • mild injection-site irritation (rare)
  • transient mild fatigue (rare)
  • occasional headache (rare)

Contraindications

  • pregnancy
  • lactation
  • active organ transplant rejection therapy
  • systemic immunosuppression for autoimmune disease (relative)
  • severe active autoimmune disease (caution)

Interactions

  • interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
  • calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
  • antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
  • vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)

Which Should You Take?

Testosterone comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Thymosin Alpha-1 is the right call when one of the conditionals below applies.

Edge case: If you cannot self-administer injections, Testosterone is the only oral option in this pair.

Default choice: Testosterone. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Thymosin Alpha-1 only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Testosterone and Thymosin Alpha-1?

Testosterone and Thymosin Alpha-1 differ in category (hormone vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Testosterone or Thymosin Alpha-1?

Testosterone half-life is 192 hours; Thymosin Alpha-1 half-life is 2 hours.

Can you stack Testosterone with Thymosin Alpha-1?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper